GO:0160075 non-canonical inflammasome complex assembly: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160075 describes the biological process of non-canonical inflammasome complex assembly, which is triggered by direct binding of intracellular lipopolysaccharide (LPS) to caspase-4/5 in humans and caspase-11 in mice.
• Unlike canonical inflammasomes that use NLR sensors, the non-canonical inflammasome relies on caspase-4/5/11 as the receptor and executor, leading to pyroptosis and IL-1beta/IL-18 maturation.
• Key components include caspase-4 (CASP4), caspase-5 (CASP5), caspase-11 (Casp11 in mice), gasdermin D (GSDMD), and NLRP3, which can be engaged downstream.
• Non-canonical inflammasome assembly is implicated in sepsis, inflammatory diseases, and host defense against Gram-negative bacteria such as Salmonella.
• Pharmacological inhibitors like methylene blue and tivantinib can suppress non-canonical inflammasome activation, highlighting therapeutic potential.
• Research methods to study this process include CRISPR knockout of CASP4/CASP5/GSDMD, pyroptosis assays, cytokine profiling, and inflammasome reconstitution systems.
Description
The non-canonical inflammasome complex assembly (GO:0160075) is a biological process that has emerged as a critical innate immune mechanism distinct from canonical inflammasome pathways. It is defined as the aggregation, arrangement and bonding together of a set of components to form a non-canonical inflammasome complex. This process is primarily driven by the direct recognition of intracellular lipopolysaccharide (LPS) by inflammatory caspases, specifically caspase-4 and caspase-5 in humans and caspase-11 in mice. Unlike canonical inflammasomes that rely on NLR or AIM2-like sensors, the non-canonical inflammasome uses these caspases as both sensors and effectors, leading to a rapid inflammatory response. Understanding this process is essential for researchers studying sepsis, pyroptosis, and inflammatory diseases, as it represents a key node in host-pathogen interactions. The assembly of this complex triggers downstream events including gasdermin D (GSDMD) cleavage, membrane pore formation, and release of pro-inflammatory cytokines. This article provides a comprehensive overview of the molecular mechanisms, key genes, disease relevance, and research methodologies associated with GO:0160075, based on authoritative QuickGO data and verified PubMed literature.
non-canonical inflammasome complex assembly At A Glance
| GO ID | GO:0160075 |
|---|---|
| GO term | non-canonical inflammasome complex assembly |
| Ontology | biological_process |
| Synonym | None |
| Major function | Assembly of a multiprotein complex that mediates inflammatory caspase activation in response to intracellular LPS, leading to pyroptosis and cytokine release. |
| Key triggers | Intracellular lipopolysaccharide (LPS) from Gram-negative bacteria. |
| Core components | Caspase-4, caspase-5, caspase-11 (mice), gasdermin D, and downstream NLRP3. |
| Cellular outcome | Pyroptosis, IL-1beta and IL-18 maturation and release. |
| Related diseases | Sepsis, inflammatory diseases, and host defense against bacterial infections. |
What Is GO:0160075?
GO:0160075, non-canonical inflammasome complex assembly, is the biological process in which a set of protein components aggregate, arrange, and bond together to form a non-canonical inflammasome complex. This process is distinct from canonical inflammasome assembly because it does not require typical NLR sensors; instead, it is initiated by the direct binding of intracellular LPS to inflammatory caspases such as caspase-4/5/11, leading to their oligomerization and activation.
Why Is non-canonical inflammasome complex assembly Important in Cell Biology?
Non-canonical inflammasome complex assembly is a cornerstone of innate immunity against Gram-negative bacterial infections, but its dysregulation contributes to severe inflammatory pathologies such as sepsis and cytokine storm. Unlike canonical inflammasomes, this pathway directly senses intracellular LPS, providing a rapid response mechanism that is independent of Toll-like receptor signaling. Understanding its assembly and regulation is crucial for developing targeted therapies for inflammatory diseases, as evidenced by studies showing that inhibitors like methylene blue and tivantinib can modulate non-canonical inflammasome activation.
• Provides a primary defense mechanism against Gram-negative bacteria by detecting intracellular LPS.
• Drives pyroptosis, a lytic form of cell death that releases inflammatory contents and alerts the immune system.
• Contributes to the pathogenesis of sepsis and septic shock through excessive cytokine release.
• Is implicated in inflammatory diseases such as diabetic nephropathy via NLRP3 cross-talk.
• Serves as a target for anti-inflammatory drugs like methylene blue and tivantinib.
• Plays a role in host-pathogen interactions, including Salmonella infection.
• Distinct from canonical inflammasomes, offering unique research and therapeutic opportunities.
• Involves caspase-4/5/11 as central effectors, making them attractive targets for CRISPR-based studies.
• Its assembly can be studied using reconstitution systems and knockout models.
• Dysregulation is linked to autoinflammatory conditions and potential cancer-related inflammation.
What Happens During non-canonical inflammasome complex assembly?
LPS Recognition and Caspase Activation
In simple terms: The process starts when bacterial LPS inside the cell is detected by caspase-4/5/11, which then activate each other.
Non-canonical inflammasome assembly begins with the direct binding of intracellular lipopolysaccharide (LPS) to the CARD domain of inflammatory caspases, specifically caspase-4 and caspase-5 in humans and caspase-11 in mice. This binding induces oligomerization and proximity-induced autoactivation of these caspases, forming the core of the non-canonical inflammasome complex. Unlike canonical inflammasomes, no NLR sensor is required for this initial recognition step.
Gasdermin D Cleavage and Pore Formation
In simple terms: Activated caspases cut gasdermin D, which then forms holes in the cell membrane, causing the cell to burst and release inflammatory signals.
Once activated, caspase-4/5/11 cleave gasdermin D (GSDMD) at a specific site, releasing its N-terminal fragment that inserts into the plasma membrane to form pores. These pores disrupt ionic gradients and lead to pyroptosis, a lytic cell death that releases IL-1beta and IL-18. GSDMD cleavage is a hallmark of non-canonical inflammasome assembly and is essential for its downstream effects.
Downstream NLRP3 Engagement
In simple terms: The non-canonical inflammasome can also activate the NLRP3 inflammasome, amplifying the inflammatory response.
Although non-canonical inflammasome assembly is independent of NLRP3 for initial LPS sensing, it can trigger NLRP3 activation downstream, leading to caspase-1 activation and further IL-1beta maturation. This cross-talk between non-canonical and canonical pathways amplifies inflammation and is relevant in diseases like diabetic nephropathy. The exact mechanism involves potassium efflux and other cellular signals.
Complex Assembly and Stoichiometry
In simple terms: Multiple caspase molecules come together to form a large complex that is stable and highly active.
The non-canonical inflammasome complex is a high-molecular-weight oligomer composed of activated caspases. Studies suggest that caspase-11 forms oligomers upon LPS binding, which are necessary for its catalytic activity. The assembly process is driven by CARD-CARD interactions and may involve additional cofactors, though the precise stoichiometry remains an area of active research.
Key Genes Involved in GO:0160075 non-canonical inflammasome complex assembly
The following genes and proteins are central to non-canonical inflammasome complex assembly, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CASP4 | Human caspase-4; directly binds intracellular LPS and initiates non-canonical inflammasome assembly. | Knockout studies to assess LPS sensing and pyroptosis. |
| CASP5 | Human caspase-5; functions similarly to caspase-4 in LPS recognition. | CRISPR knockout to study redundancy with CASP4. |
| CASP11 (mouse) | Mouse caspase-11; ortholog of human caspase-4/5, essential for non-canonical inflammasome in mice. | Mouse models for sepsis and bacterial infection. |
| GSDMD | Gasdermin D; cleaved by caspases to form membrane pores and induce pyroptosis. | Knockout models to block pyroptosis and study cytokine release. |
| NLRP3 | NLRP3 inflammasome; engaged downstream of non-canonical activation, amplifying inflammation. | Cross-talk studies and disease models. |
| IL1B | Interleukin-1 beta; pro-inflammatory cytokine matured and released upon pyroptosis. | Cytokine profiling and knockout models. |
| IL18 | Interleukin-18; another cytokine released during pyroptosis. | Measurement in inflammatory diseases. |
| AIM2 | Absent in melanoma 2; canonical inflammasome sensor, not directly involved in non-canonical assembly but can be co-activated. | Comparative studies with non-canonical pathways. |
| NLRC4 | NLRC4 inflammasome; canonical sensor, may interact with non-canonical pathways. | Inhibitor studies and cross-talk. |
| CASP1 | Caspase-1; canonical inflammasome effector, activated downstream of NLRP3. | Distinguishing canonical vs non-canonical responses. |
| PYCARD | ASC; adaptor protein for canonical inflammasomes, not required for non-canonical assembly. | Knockout to differentiate pathways. |
| TLR4 | Toll-like receptor 4; primes canonical inflammasomes but not directly involved in non-canonical assembly. | Priming studies. |
| NFKB1 | NF-kB; transcription factor for inflammasome priming, not assembly. | Priming and expression studies. |
| IRF1 | Interferon regulatory factor 1; regulates caspase-11 expression in mice. | Knockout to study non-canonical inflammasome priming. |
| GBP1 | Guanylate-binding protein 1; promotes lysis of bacteria and LPS release. | Host-pathogen interaction studies. |
| GBP2 | Guanylate-binding protein 2; similar to GBP1 in facilitating LPS access. | Knockout models. |
| IRGB10 | Interferon-inducible GTPase; targets bacteria for LPS release. | Mouse infection models. |
| CASP8 | Caspase-8; can modulate non-canonical inflammasome activation. | Cross-talk studies. |
How Is non-canonical inflammasome complex assembly Regulated?
Non-canonical inflammasome complex assembly is tightly regulated at multiple levels. Transcriptionally, caspase-11 expression in mice is induced by interferon regulatory factor 1 (IRF1) and type I interferons, while human caspase-4/5 are constitutively expressed but can be upregulated by inflammatory stimuli. Post-translationally, the assembly is controlled by LPS availability, which depends on bacterial lysis mediated by guanylate-binding proteins (GBPs) and IRGB10. Additionally, NLRP3 cross-talk can amplify the response, and inhibitors like methylene blue and tivantinib can suppress assembly. The process is also modulated by cellular potassium efflux and other ionic changes.
non-canonical inflammasome complex assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CASP11 | Sepsis and endotoxemia in mice. | Casp11 knockout mice challenged with LPS. |
| CASP4 | Human inflammatory diseases and bacterial infections. | CASP4 knockout human macrophages. |
| GSDMD | Pyroptosis-related inflammatory diseases. | Gsdmd knockout mice and cell lines. |
| NLRP3 | Diabetic nephropathy and autoinflammatory diseases. | Nlrp3 knockout mice in diabetes models. |
| IL1B | Cytokine storm and fever syndromes. | Il1b knockout mice and cytokine assays. |
Sepsis and Septic Shock
Non-canonical inflammasome assembly is a major driver of sepsis pathogenesis. Excessive activation by intracellular LPS from Gram-negative bacteria leads to massive pyroptosis and release of IL-1beta and IL-18, contributing to cytokine storm and organ failure. Mouse models with caspase-11 deficiency are protected from LPS-induced septic shock, highlighting the therapeutic potential of targeting this pathway.
Inflammatory Kidney Diseases
The NLRP3 inflammasome, which can be engaged downstream of non-canonical assembly, plays a significant role in diabetic nephropathy. Studies show that NLRP3 activation mediates glomerular and tubular injury in diabetic kidneys, and non-canonical pathways may contribute to this process. Targeting non-canonical inflammasome components could offer renoprotective strategies.
Bacterial Infections and Host Defense
Non-canonical inflammasome assembly is critical for defense against Gram-negative pathogens like Salmonella. Human cells activate caspase-4/5 upon Salmonella infection, leading to pyroptosis and bacterial clearance. However, excessive activation can cause tissue damage, as seen in severe infections.
Cancer and Inflammation
Chronic inflammation driven by non-canonical inflammasome activation may promote tumorigenesis. NLRP3, a downstream effector, has been implicated in various cancers, and inhibitors like tivantinib that target this pathway are being explored for anti-inflammatory and anti-cancer effects. Further research is needed to fully elucidate the role of GO:0160075 in cancer.
From non-canonical inflammasome complex assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CASP4 mediate non-canonical inflammasome assembly in human cells? | CASP4 knockout in THP-1 or primary macrophages. |
| What is the role of GSDMD in pyroptosis? | GSDMD knockout mice and cell lines. |
| Can a point mutation in CASP4 abolish LPS binding? | CRISPR point mutation knock-in of CASP4 catalytic or CARD domain mutants. |
| How does NLRP3 cross-talk with non-canonical inflammasome? | NLRP3 knockout mice combined with LPS challenge. |
| What is the effect of caspase-11 overexpression? | Casp11 overexpression in mouse macrophages. |
| Can we track non-canonical inflammasome assembly in live cells? | Tagged knock-in of CASP4 or GSDMD with fluorescent proteins. |
How to Study the non-canonical inflammasome complex assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Validate CASP4/CASP5/GSDMD roles. |
| LDH release assay | Pyroptosis | Screen for inhibitors or gene knockouts. |
| ELISA | IL-1beta and IL-18 levels | Quantify inflammasome activation. |
| Western blot | Caspase and GSDMD cleavage | Confirm pathway activation. |
| Fluorescence microscopy | Complex assembly and localization | Track tagged proteins. |
| Co-immunoprecipitation | Protein-protein interactions | Identify complex components. |
| RNA-seq | Transcriptional changes | Study priming and regulation. |
| In vivo LPS challenge | Septic shock and survival | Test caspase-11 knockout mice. |
CRISPR Knockout and Knock-in Models
CRISPR-Cas9 technology is widely used to generate knockout cell lines and mice for key genes such as CASP4, CASP5, CASP11, and GSDMD. These models are essential to dissect the specific contributions of each component to non-canonical inflammasome assembly. Knock-in of point mutations or tags allows real-time tracking of complex formation.
Pyroptosis and Cytotoxicity Assays
Pyroptosis is measured by LDH release, propidium iodide staining, or live-cell imaging. These assays quantify the end-point of non-canonical inflammasome assembly and are used to screen inhibitors or validate genetic knockouts.
Cytokine Profiling
ELISA and multiplex assays for IL-1beta and IL-18 are standard to assess inflammasome activation. Supernatants from LPS-primed and transfected cells are analyzed to measure cytokine release.
Inflammasome Reconstitution and Imaging
Reconstitution of non-canonical inflammasome components in vitro or in cells with fluorescent tags enables visualization of assembly. Confocal microscopy and FRET can reveal oligomerization dynamics.
How CRISPR Can Be Used to Study GO:0160075 non-canonical inflammasome complex assembly
Knockout
CRISPR knockout of CASP4, CASP5, CASP11, or GSDMD is used to abolish non-canonical inflammasome assembly and downstream pyroptosis. These models help determine the necessity of each gene in LPS sensing and inflammatory responses.
Point Mutation
Point mutations can be introduced into the catalytic domain of caspases or the cleavage site of GSDMD to study specific residues required for assembly and function. For example, mutating the catalytic cysteine of caspase-11 prevents autoactivation.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags into endogenous loci allows real-time imaging and biochemical isolation of the non-canonical inflammasome complex. This approach provides insights into assembly dynamics and stoichiometry.
Overexpression
Overexpression of caspase-11 or GSDMD in cell lines can amplify non-canonical inflammasome responses, facilitating biochemical studies and inhibitor screening. However, overexpression may bypass normal regulatory mechanisms.
How EDITGENE Supports non-canonical inflammasome complex assembly Research
Researchers studying non-canonical inflammasome complex assembly-related genes often need to determine whether a candidate gene is causally involved in LPS sensing, complex formation, or pyroptosis. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for non-canonical inflammasome complex assembly research.
Frequently Asked Questions About non-canonical inflammasome complex assembly
What is GO:0160075?
GO:0160075 is the Gene Ontology term for non-canonical inflammasome complex assembly, the process by which a multiprotein complex forms in response to intracellular LPS, leading to inflammatory caspase activation.
What genes are involved in non-canonical inflammasome complex assembly?
Key genes include CASP4, CASP5, CASP11 (mouse), GSDMD, and NLRP3, which are central to complex formation and downstream signaling.
How is the non-canonical inflammasome different from the canonical inflammasome?
The non-canonical inflammasome directly senses intracellular LPS via caspase-4/5/11, whereas canonical inflammasomes use NLR or AIM2 sensors to detect diverse ligands.
What diseases are associated with non-canonical inflammasome complex assembly?
It is implicated in sepsis, inflammatory kidney diseases, and host defense against Gram-negative bacteria such as Salmonella.
What methods are used to study non-canonical inflammasome assembly?
Common methods include CRISPR knockout, pyroptosis assays, cytokine profiling, Western blot for caspase/GSDMD cleavage, and imaging of tagged proteins.
Can non-canonical inflammasome assembly be inhibited?
Yes, compounds like methylene blue and tivantinib have been shown to inhibit non-canonical inflammasome activation, offering therapeutic potential.
What is the role of gasdermin D in non-canonical inflammasome assembly?
Gasdermin D is cleaved by activated caspases to form membrane pores, leading to pyroptosis and release of IL-1beta and IL-18.
How does LPS trigger non-canonical inflammasome assembly?
Intracellular LPS binds directly to the CARD domain of caspase-4/5/11, inducing their oligomerization and autoactivation, which initiates complex assembly.
Is NLRP3 involved in non-canonical inflammasome assembly?
NLRP3 is not required for initial LPS sensing but can be activated downstream, amplifying the inflammatory response through caspase-1.
What model systems are available to study non-canonical inflammasome assembly?
Researchers use knockout mice (e.g., Casp11-/-), human macrophage cell lines (e.g., THP-1), and reconstitution systems with recombinant proteins.
Conclusion
Non-canonical inflammasome complex assembly (GO:0160075) is a vital innate immune process that detects intracellular LPS and triggers pyroptosis and inflammation. Its unique mechanism, centered on caspase-4/5/11 and gasdermin D, distinguishes it from canonical inflammasome pathways and makes it a promising target for treating sepsis and inflammatory diseases. Continued research using CRISPR models and advanced screening techniques will further elucidate its regulation and therapeutic potential.
References
- 1. Accogli T et al.. 2023. Canonical and non-canonical functions of NLRP3.. J Adv Res 53:137-151 PMID: 36610670
- 2. Xiao TS. 2015. The nucleic acid-sensing inflammasomes.. Immunol Rev 265(1):103-11 PMID: 25879287
- 3. Bierschenk D et al.. 2017. Salmonella-induced inflammasome activation in humans.. Mol Immunol 86:38-43 PMID: 27974148
- 4. Abu Khweek A et al.. 2020. Pyroptotic and non-pyroptotic effector functions of caspase-11.. Immunol Rev 297(1):39-52 PMID: 32737894
- 5. Ahn H et al.. 2017. Methylene blue inhibits NLRP3, NLRC4, AIM2, and non-canonical inflammasome activation.. Sci Rep 7(1):12409 PMID: 28963531
- 6. Huang Y et al.. 2023. Tivantinib alleviates inflammatory diseases by directly targeting NLRP3.. iScience 26(3):106062 PMID: 36843841
- 7. Williams BM et al.. 2022. The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy.. Front Physiol 13:907504 PMID: 35755447
- 8. Vanaja SK et al.. 2015. Mechanisms of inflammasome activation: recent advances and novel insights.. Trends Cell Biol 25(5):308-15 PMID: 25639489
